A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer (RxPonder) is another clinical trial that utilized genomic testing to further narrow our scope of adjuvant chemotherapy, reporting benefits over adjuvant endocrine therapy alone in HR-positive, HER2-negative pre-menopausal patients with 1–3 positive nodes with low recurrence scores but not in post-menopausal patients of the same type. The gene discussed is ERBB2; the disease is breast carcinoma.